About P&T JournalContacts:
Statement of Purpose
Guidelines for Authors
Letter to the Editor
Fred J. Pane, RPh, BSPharm, FASHP
Treatment-resistant depression is extremely common—but does that mean there is no place for antidepressants?
David A. Casey, MD
Health Care & Law
New Features in 2013
Among the health care changes this year: revenues to hospitals will be lower, payments to physicians will be modified, and more patients will be covered by Medicaid.
E. Paul Larrat, RPh, PhD; Rita M. Marcoux, RPh, MBA; and F. Randy Vogenberg, RPh, PhD
Composition of Formularies Is a Point of Contention
it is unclear how the final rule on “clinically appropriate” and “medically necessary” drugs will apply to hospital formularies and Part B drugs given in the doctor’s office.
Are Your Patients at Risk?
The author presents 4 case histories of patients who experienced angioedema after treatment with various ACE inhibitors in what some have called a “silent epidemic.”
Michele B. Kaufman, PharmD, RPh
Three agents have recently been approved to reduce the risk of stroke and embolism, and one agent is in phase 3 trials. These drugs cause less serious bleeding and are simpler to manage, compared with warfarin, but they are not without their risks.
John R. Fanikos, MBA, RPh; Julie K. Atay, PharmD, MBA; and Jean M. Connors, MD
Borrowing and lending drugs is a dangerous business.
Matthew Grissinger, RPh, FASCP
Accessing Formularies in Health Plans Is a Major Problem
The DHHS pushes to expand e-prescribing. Pharmacy groups push back.
FDA approvals, drug indications, and updates
Bedaquiline for multiresistant pulmonary tuberculosis; Flublok influenza vaccine; and Octaplas for coagulation factor deficiency
Marvin M. Goldenberg, PhD, RPh, MS
Linaclotide (Linzess) for Irritable Bowel Syndrome With Constipation and for Chronic Idiopathic Constipation
Linaclotide (Linzess) for irritable bowel syndrome with constipation and for chronic idiopathic constipation
Rachel Hutchins Thomas, PharmD, MS; and Kyle Allmond